Sandoz receives Canada approval for generic Ozempic
Sandoz Group said Canada’s drug regulator has approved its generic version of Novo Nordisk’s Ozempic, supporting its GLP-1 portfolio plans.
Sandoz Group said it received approval from Canada’s drug regulator for its generic version of Novo Nordisk’s Ozempic, a blockbuster diabetes drug, advancing its efforts to build a portfolio of so-called GLP-1 medicines. The Swiss maker of generic drugs said Friday that Health Canada…